Neutralizing and binding anti-interferon-β (IFN-β) antibodies. A comparison between IFN-β-1a and IFN-β-1b treatment in multiple sclerosis

European Journal of Neurology

Volumn 7, Issue 1, 2000, Pages 27-34

  Kivisakk P ^a   Alm, G V ^b   Fredrikson, S ^a   Link, H ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Antibodies; Interferon ; Multiple sclerosis; Treatment

Indexed keywords

BETA1A INTERFERON; INTERFERON ANTIBODY; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ADULT; ARTICLE; CROSS REACTION; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, BLOCKING; ANTIBODY SPECIFICITY; BIOLOGICAL ASSAY; FEMALE; HUMANS; IMMUNOASSAY; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROTEIN BINDING; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 0034455447     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2000.00002.x     Document Type: Article

References (25)

1. Interferons and multiple sclerosis
2. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-α) in normal and transgenic mice
3. H-2 genetic control of the response of T lymphocytes to insulins. Priming of nonresponder mice by forbidden variants of specific antigenic determinants
4. The Multiple Sclerosis PRISMS Study: Prevention of relapses and disability by interferon-beta 1a subcutaneously in multiple sclerosis
5. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukemia: Dose dependency of response and frequency of neutralizing anti-interferon antibodies
6. Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-α) during therapy for chronic hepatitis C
7. The detection of antibodies to recombinant interferon alfa-2a in human serum
8. Intramuscular interferon beta-la for disease progression in relapsing Multiple Sclerosis
9. Quantification of neutralisation of interferon by antibody
10. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous injection
11. Neutralising and binding anti-interferon-β-1b (IFN-β-1b) antibodies during IFN-β-1b treatment of multiple sclerosis
12. Multiple sclerosis: Myelin basic protein induced mRNA expression of proinflammatory cytokines in mononuclear cells is suppressed by interferon-β-1b in vitro
13. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
14. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: Plight of the practising neurologist
15. Interferon immunogenicity: Preclinical evaluation of interferon-α 2a
16. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis
17. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
18. Antibodies that neutralize human beta interferon biologic activity recognize a linear epitope: Analysis by synthetic epitope mapping
19. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
20. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β)
21. Characterisation of anti-interferon-α antibodies appearing during recombinant interferon-α2a treatment
22. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomised controlled trial
23. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years
24. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: Development of neutralising interferon antibodies and possible loss of antitumor activity